GILD

Gilead Sciences, Inc. News Headlines

$93.27
*  
1.98
2.17%
Get GILD Alerts
*Delayed - data as of Dec. 26, 2014 12:39 ET  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Cramer's Lightning Round - Energy XXI Is The Worst Stock I've Ever Been Associated With (10/2/14)
10/3/2014 6:18:00 AM - Seeking Alpha


Growth Portfolio World Series
10/3/2014 2:03:00 AM - Seeking Alpha


Top Fund Buys: Chipotle, Allergan, Jazz, Gilead
10/2/2014 5:25:00 PM - Investor's Business Daily


Progenics/Salix's Relistor Label Expanded in the U.S. - Analyst Blog
10/2/2014 4:20:00 PM - Zacks.com


AbbVie's (ABBV) Humira Gains Yet Another FDA Approval - Analyst Blog
10/2/2014 4:00:00 PM - Zacks.com


Achillion: Positioned To Deliver The Last Clinical Stage Nuc To The Highest Bidder
10/2/2014 2:48:00 PM - Seeking Alpha


AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data - Analyst Blog
10/2/2014 2:30:00 PM - Zacks.com


Seattle Genetics-Takeda Reveal Impressive Adcetris Data - Analyst Blog
10/1/2014 2:30:00 PM - Zacks.com


Machines Rule, Bears Drool - Video Blog
10/1/2014 2:09:36 PM - Zacks.com


Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?
10/1/2014 11:37:17 AM - Motley Fool


Round 2 of Gilead Sciences, Inc.'s Offensive Begins
10/1/2014 8:23:02 AM - Motley Fool


#PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed
10/1/2014 6:42:39 AM - Benzinga


AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog
9/30/2014 4:10:00 PM - Zacks.com


CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
9/30/2014 4:10:00 PM - Zacks.com


Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
9/30/2014 3:30:00 PM - Zacks.com


4 Predictions For The Fourth Quarter
9/30/2014 9:50:00 AM - Seeking Alpha


Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% - Tale of the Tape
9/30/2014 8:46:00 AM - Zacks.com


Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session - Tale of the Tape
9/30/2014 8:39:00 AM - Zacks.com


Gilead Sciences, Inc. Stock's Stunning New Opportunity
9/30/2014 8:15:02 AM - Motley Fool


Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape
9/30/2014 7:36:00 AM - Zacks.com


Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog
9/29/2014 5:50:00 PM - Zacks.com


Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog
9/29/2014 4:55:00 PM - Zacks.com


Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
9/29/2014 4:30:00 PM - Zacks.com


Gilead's HCV Combo Drug Harvoni Secures CHMP Backing - Analyst Blog
9/29/2014 4:20:00 PM - Zacks.com


Nektar/AstraZeneca's Moventig a Step Closer to EU Approval - Analyst Blog
9/29/2014 4:10:00 PM - Zacks.com